GlassScriptPhysician profile
Rachel A Thomas
NPI 1386390219
$1,813.37
in general payments reported to CMS, 2019-2025
25 companies · $734 in 2025
The $734 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $431 · 2024: $399 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,563 · Education: $1.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,562.93 |
| Education | $1.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $287.91 | 2023-2025 | Fetroja |
| Paratek Pharmaceuticals, INC. | $266.87 | 2022-2025 | Nuzyra |
| Abbvie INC. | $259.95 | 2022-2025 | |
| Gilead Sciences, INC. | $189.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $128.51 | 2024-2025 | Zerbaxa, Dificid, Delstrigo |
| Insmed, INC. | $110.48 | 2022-2024 | Arikayce |
| Dynavax Technologies Corporation | $76.94 | 2023 | Heplisav-B |
| Novo Nordisk INC | $67.36 | 2022-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $49.26 | 2022-2025 | Mounjaro, Zepbound |
| Viiv Healthcare Company | $47.21 | 2025 | Dovato, Cabenuva |
| Aimmune Therapeutics, INC. | $39.76 | 2024-2025 | Vowst |
| Harmony Biosciences LLC | $31.84 | 2025 | |
| Exact Sciences Corporation | $30.35 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $28.97 | 2025 | Veozah |
| Vanda Pharmaceuticals INC. | $26.46 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $25.58 | 2025 | Defencath |
| Amgen INC. | $21.13 | 2024 | Evenity, Prolia |
| Csl Behring | $20.35 | 2023 | Kcentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.17 | 2023 | Jardiance |
| Amneal Pharmaceuticals LLC | $15.37 | 2022 | |
| Seqirus USA INC | $15.07 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $14.94 | 2025 | Farxiga |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.93 | 2023 | Xifaxan |
| Janssen Pharmaceuticals, INC | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.